Adverum Biotechnologies, Inc. has 8 Schedule 13D or 13G filings on record since 2025-07-16. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.
Stated intent
Intent stated in Item 4 BML Investment Partners, L.P.
On November 10, 2025, the Reporting Persons sent a letter to the Board of the Issuer detailing the Reporting persons dissapointment with the current deal with Lilly and the lack of a full sale process.From Item 4 of the SCHEDULE 13D/A filed 2025-11-10
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock, Inc. | 2% | 414,485 | SCHEDULE 13G/A, 2025-07-16 | 2025-06-30 |
| Franklin Resources, Inc. | 0% | 0 | SCHEDULE 13G/A, 2025-08-05 | 2025-06-30 |
| Frazier Life Sciences Public Fund, L.P. | 0% | 0 | SCHEDULE 13G/A, 2025-12-09 | 2025-12-09 |
| BML Investment Partners, L.P. | 0% | 0 | SCHEDULE 13D/A, 2025-12-09 | 2025-12-09 |
Purpose of Transaction (Item 4)
BML Investment Partners, L.P.
All of the Common Stock of the Issuer reported on this Schedule 13D was acquired in the ordinary course of business by the reporting persons for investment purposes. The reporting persons have no present plans or proposals that relate to or would result in any of the actions described in Item 4(a) through (j) of Schedule 13D. The reporting persons may evaluate on a continuing basis the investment in the Issuer and may, from time to time, acquire or dispose of Common Stock of the Issuer. Any such acquisitions or dispositions will depend upon (i) the price and availability of the Issuer's securities; (ii) subsequent developments concerning the Issuer's business and prospects and the industry in which the Issuer operates; (iii) investment policies of the reporting persons; (iv) other investment opportunities available to the reporting persons; (v) general market and economic conditions; (vi) tax considerations; and (viii) such other factors as the reporting persons may deem relevant. Any such acquisitions or dispositions may be made, subject to applicable law, in open market transactions. As with their other investments, the Reporting Persons continuously evaluate the Issuer, including, but not limited to, its businesses, operations and prospects. The Reporting Persons may engage in discussions with the Issuer and its representatives and/or other stockholders, seek to enter into a confidentiality agreement with the Issuer and/or discuss with the Issuer different strategic …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-12-09; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | BlackRock, Inc. | 2% | SCHEDULE 13G/A |
| 2025-08-05 | Franklin Resources, Inc. | 0% | SCHEDULE 13G/A |
| 2025-08-14 | Frazier Life Sciences Public Fund, L.P. | 5.4% | SCHEDULE 13G/A |
| 2025-11-10 | BML Investment Partners, L.P. intent stated | 15.6% | SCHEDULE 13D/A |
| 2025-11-28 | Frazier Life Sciences Public Fund, L.P. | 19.4% | SCHEDULE 13G/A |
| 2025-12-05 | BML Investment Partners, L.P. | 9.7% | SCHEDULE 13D/A |
| 2025-12-09 | Frazier Life Sciences Public Fund, L.P. | 0% | SCHEDULE 13G/A |
| 2025-12-09 | BML Investment Partners, L.P. | 0% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for Adverum Biotechnologies, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.